Novelion Therapeutics Inc. (NASDAQ:NVLN) Files An 8-K Other EventsItem 8.01. Other Events.
The board of directors of Novelion Therapeutics Inc. (“the Company”) has established August 9, 2018 as the date of the Company’s 2018 annual meeting of shareholders (the “2018 Annual Meeting”) and July 6, 2018 as the record date for determining shareholders entitled to vote at the 2018 Annual Meeting.
The deadline for director nominations for the 2018 Annual Meeting in accordance with the Company’s Advance Notice Policy, as well as for any shareholder proposals for inclusion in the Company’s proxy materials for the 2018 Annual Meeting to Rule 14a-8 under the Securities Exchange Act of 1934, as amended, is July 9, 2018. Nominations must comply with the requirements of the Company’s Advance Notice Policy and any proposals submitted to Rule 14a-8 of the Exchange Act must comply with the applicable rules of the Securities and Exchange Commission. Nominations and shareholder proposals must be sent to the Company’s registered office located at 1800 – 510 West Georgia Street, Vancouver, British Columbia, Canada V6B 0M3.
The time and location of the 2018 Annual Meeting will be as set forth in the Company’s proxy statement for the 2018 Annual Meeting.
About Novelion Therapeutics Inc. (NASDAQ:NVLN)
Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company’s portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.